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INTRODUCRTION 
Amongst the various routes of drug delivery , oral route is 
perhaps the most preferred to the patient and the clin ician  
alike because oral mucosa is relat ively permeable with a 
rich blood supply, it is robust and shows short recovery 
times after stress or damage
 1-4
, and the virtual lack of 
Langerhans cells
 5
 makes the oral mucosa tolerant to 
potential allergens. Within the oral mucosal cavity, the 
buccal region offers an attractive route of administration 
for systemic drug delivery of potent peptide and perhaps 
protein drug molecules. The mucosa has a rich blood 
supply and it is relatively permeable.  
Buccal delivery involves the administration of the desired 
drug through the buccal mucosal membrane lining of the 
oral cavity. Unlike oral d rug delivery, which presents a 
hostile environment for d rugs, especially p roteins and 
polypeptides, due to acid hydrolysis and the hepatic first-
pass effect, the mucosal lin ing of buccal tissues provides a 
much milder environment for drug absorption.  
Additionally, buccal drug delivery has a high patient 
acceptability compared to other non-oral routes of drug 
administration. Harsh environmental factors that exist in 
oral delivery of a d rug are circumvented by buccal 
delivery. Avoiding acid hydrolysis in the gastrointestinal 
(GI) tract and bypassing the first-pass effect are some of 
the advantages of this route of drug delivery. Moreover, 
rapid cellular recovery and achievement of a localized site 
on the smooth surface of the buccal mucosa are among the 
other advantages of this route of drug delivery.  
The disadvantages associated with this route of drug 
delivery are the low permeability of the buccal membrane
6
, 
specifically when compared to the sublingual membrane
7,8
,  
 
and a smaller surface area. The total surface area of the 
membranes of the oral cavity available for drug absorption 
is 170 cm2 
5
, of which ~50 cm2 represents non-keratinized  
tissues, including the buccal membrane
9
. The continuous 
secretion of saliva (0.5–2 l/day) leads to subsequent 
dilution of the drug
8
. Swallowing of saliva can also 
potentially lead to the loss of dissolved or suspended drug 
and, ultimately, the involuntary removal of the dosage 
form. These are some of the problems that are associated 
with buccal drug delivery. Success of buccal drug delivery 
system based on the selection of proper excip ients and 
taking consideration of factors affecting buccal drug 
delivery i.e. physiological propert ies of drug, pathological 
state of patient and the polymer related factors etc. Thus 
present focuses on the various perspectives of buccal drug 
delivery which are necessary to consider before designing 
any dosage form. The rev iew also assesses the polymers 
used in buccal drug delivery as well as various factors 
affecting buccal adhesive drug delivery systems. 
STRUCTURE OF THE ORAL MUCOSA  
The oral mucosa is composed of an outermost layer of 
stratified squamous epithelium. Below this lies a basement 
membrane, a lamina propria followed by the submucosa as 
the innermost layer. The ep ithelium is similar to stratified  
squamous epithelia found in the rest of the body in that it 
has a mitotically active basal cell layer, advancing through 
a number of differentiating intermediate layers to the 
superficial layers, where cells are shed from the surface of 
the epithelium
 10
. The epithelium of the buccal mucosa is 
about 40-50 cell layers thick, while that of the sublingual 
epithelium contains somewhat fewer. The ep ithelial cells 
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increase in size and become flatter as they travel from the basal layers to the superficial layers. 
 
Figure 1: Structure of buccal mucosa 
The oral mucosal thickness varies depending on the site: 
the buccal mucosa measures at 500-800 µm, while the 
mucosal thickness of the hard and soft palates, the floor of 
the mouth, the ventral tongue, and the gingivae measure at 
about 100-200 µm. The composition of the epithelium also 
varies depending on the site in the oral cavity. The 
mucosae of areas subject to mechanical stress (the 
gingivae and hard palate) are keratinized similar to the 
epidermis. The mucosae of the soft palate, the sublingual, 
and the buccal regions, however, are not keratinized. The 
keratin ized epithelia contain neutral lipids like ceramides 
and acylceramides which have been associated with the 
barrier function. These epithelia are relatively  
impermeable to water. In contrast, non-keratinized  
epithelia, such as the floor of the mouth and the buccal 
epithelia, do not contain acylceramides and only have 
small amounts of ceramide
11-13
. They also contain small 
amounts of neutral but polar lip ids, main ly cholesterol 
sulfate and glucosyl ceramides. These epithelia have been 
found to be considerably more permeable to water than 
keratin ized epithelia
 10-12
. 
DRUG DELIVERY PATHWAY THROUGH 
BUCCAL MUCOSA: 
The main mechanis ms responsible for the penetration of 
various substances include simple diffusion (paracellular, 
transcellular), carrier-mediated diffusion, active transport, 
and pinocytosis or endocytosis. Recent evidence has 
shown that passive diffusion is the primary mechanis m for 
the transport of drugs across the buccal mucosa, although 
carrier-mediated transport has been reported to have a 
small ro le. Two routes of passive transport are available in  
the buccal epithelium; one involves the transport of 
compounds through the intercellular spaces between the 
cells (paracellular), and the other involves passage into and 
across the cells (transcellular). Depending on the nature of 
the permeant, i.e. the overall molecular geometry, 
lipophilicity, and charge, either of the transport pathways 
across buccal epithelium can be selected. 
While considerable evidence has been presented to 
document that most compounds diffuse through the buccal 
mucosa by passive diffusion or simple Fickian diffusion 
14
, 
some are transported by a carrier mediated process across 
the buccal mucosa. Glucose 
15
, monocarboxylic acids and 
salicylic acid 
16, 17
, and nicotinic acid 
18, 19
, are examples of 
substances which utilize a carrier-mediated diffusion 
mechanis m for permeat ion across buccal epithelium.  
 
Figure 2: Drug delivery pathway through buccal mucosa 
LOCAL AND S YSTEMIC DRUG DELIVERY VIA 
THE ORAL MUCOSA 
Absorption of drug via the mucous membranes of the oral 
cavity can occur in either the sublingual, buccal, or local 
regions. The local region includes all areas other than the 
former two regions. The oral mucosa is classified as a 
somewhat leaky epithelium with a permeability rank order 
of sublingual, buccal, palatal, based on the thickness and 
degree of keratinization of the tissues 
7
. Different regions 
of the oral cav ity vary greatly in terms of their composition 
and their potential utility in drug delivery. The thin and 
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highly permeable membrane of the sublingual tissue is a 
perfect target if a prompt onset is desired. Considerable 
surface area and high blood flow to this region provide a 
means for rapid access to the systemic circulation. 
However, if a retentive, sustained-release system is 
desired, the sublingual membrane fails to be an appropriate 
target tissue. 
Sustained-release systems, which are able to provide 
sustained drug concentrations in the systemic circulat ion 
due to delayed release of the drug from the formulation, 
are suitable dosage forms for the buccal region of the oral 
cavity. The lower permeability of th is region compared to 
the sublingual site is ideal for controlled-release systems. 
Additionally, drug delivery via this site avoids extensive 
enzyme degradation and first-pass metabolism seen with 
oral admin istrations, which are desired outcomes for the 
delivery of therapeutic proteins and peptides. However, the 
low permeability of this site is not always an attractive 
feature and, depending on the choice of drug, can be a 
major limitation. Use of sub-toxic levels of penetration 
enhancers and targeted delivery may potentially overcome 
this problem in the buccal reg ion of the oral cav ity. 
Local delivery in the oral cavity has had particular 
applications in the treatment of toothache, periodontal 
diseases, and bacterial infections. However, because of its 
specificity, local delivery does not have the broad range of 
applications that sublingual and buccal drug administration 
provides. 
MECHANIS M OF MUCOADHES ION
 20
: 
1. Hydration mediated adhesion:  
Certain hydrophilic polymers have the tendency to 
imbibe large amount of water and become sticky, 
thereby acquiring bioadhesive properties. 
2. Bonding mediated adhesion: 
For adhesion to occur, molecules must bond across 
the interface. These bonds can arise in the following 
way. 
 Ionic bonds 
 Covalent bonds 
 Hydrogen bonds 
 Vander-Waals bonds 
 Hydrophobic bonds 
POLYMERS IN BUCCAL ADHES IVE DRUG 
DELIVERY  
Mucoadhesive delivery systems are being explored fo r the 
localization of the active agents to a particular location/ 
site. Polymers have played an important role in designing 
such systems so as to increase the residence time of the 
active agent at the desired location. Polymers used in 
mucosal delivery system may be of natural or synthetic 
origin.  
Hydrophilic polymers  
The polymers within this category are soluble in water. 
Matrices developed with these polymers swell when put 
into an aqueous media with subsequent dissolution of the 
matrix. The polyelectrolyte extends greater mucoadhesive 
property when compared with neutral polymers
 21
. Anionic 
polyelectrolytes, e.g. poly (acrylic acid) and 
carboxymethyl cellulose, have been extensively used for 
designing mucoadhesive delivery systems due to their 
ability to exhibit strong hydrogen bonding with the mucin  
present in the mucosal layer
22, 23
. Chitosan provides an 
excellent example of cationic polyelectro lyte, which has 
been extensively used for developing mucoadhesive 
polymer due to its good biocompatibility and 
biodegradable properties
24
. Chitosan undergoes 
electrostatic interactions with the negatively charged 
mucin chains thereby exh ibiting mucoadhesive property
21
. 
The ionic polymers may be used to develop ionic complex 
with the counter-ionic drug molecules so as to have a drug 
delivery matrix exhib iting mucoadhesive property. 
Mucoadhesive microcapsules can be designed with same 
principle by using orifice-ionic gelation method. Non-ionic 
polymers, e .g. poloxamer, hydroxypropyl methyl cellu lose, 
methyl cellu lose, poly (vinyl alcohol) and poly (vinyl 
pyrrolidone), have also been used for mucoadhesive 
properties
21
. Cellu lose and its derivates have been reported 
to have surface active property in addition to its film 
forming capability
 24, 25
. Cationic cellu lose derivatives (e.g. 
cationic hydroxyethyl celluloses) have been used in 
conjunction with various anionic polymers for the 
development of mucoadhesive sustained delivery systems
 
21, 26
.  
Hydrogels  
Hydrogels can be defined as three-dimensionally cross 
linked polymer chains which have the ability to hold water 
within  its porous structure due to the presence of 
hydrophilic functional groups like hydroxyl, amino and 
carboxyl groups. In general, with the increase in the cross 
linking density there is an associated decrease in the 
mucoadhesion
 27
. Thielmann et al. reporteds the thermal 
cross linking of poly (acrylic acid) and methyl cellu lose. 
They reported that with the increase in the cross linking 
density, there was a reduction in the solubility parameters 
and swelling which resulted in a reduction of 
mucoadhesion
 27
.  
Thiolated polymers :  
The presence of free thiol groups in the polymeric skeleton 
helps in the formation of disulphide bonds with that of the 
cysteine-rich sub-domains present in mucin which can 
substantially improve the mucoadhesive properties of the 
polymers (e.g. poly (acry lic acid ) and chitosan) in addition 
to the paracellular uptake of the bioactive agents
 28-32
. 
Various thiolated polymers include chitosan–
iminothiolane, poly (acrylic acid)–cysteine, poly (acrylic 
acid)–homocysteine, chitosan–thioglycolic acid, chitosan–
thioethylamid ine, alg inate–cysteine, poly (methacrylic 
acid)–cysteine and sodium carboxymethylcellu lose–
cysteine
22
.  
Lectin-based polymers:  
Lectins are proteins which have the ability to reversibly 
bind with specific sugar / carbohydrate residues and are 
found in both animal and plant kingdom in addit ion to 
various microorganis ms 
33-35
. Many lectins have been 
found to be toxic and immunogenic which may lead to 
systemic anaphylaxis in susceptible individuals on 
subsequent exposure
 22
. The specific affinity of lectins 
towards sugar or carbohydrate residues provides them with 
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specific cytoadhesive property and is being explored to 
develop targeted delivery systems. The various lectins 
which have shown specific binding to the mucosa include 
lectins extracted from Ulex europaeus I, soybean, peanut 
and Lens culinarius
36
.  
FACTORS AFFECTING MUCOADHES ION IN THE 
BUCCAL CAVITY 
 A variety of factors affect the mucoadhesion in the buccal 
cavity are discussed below: 
1. Polymer-related factors 
1.1. Molecular weight  
In general, it has been shown that the bioadhesive 
strength of a polymer increases with molecu lar 
weights above 100,000 8. As one example, the direct 
correlation between the bioadhesive strength of 
polyoxyethylene polymers and their molecu lar 
weights, in the range of 200,000 to 7,000,000, has 
been shown by Tiwari et al.
 37
 
1.2. Flexibility 
Bioadhesion starts with the diffusion of the polymer 
chains in the interfacial reg ion. Therefore, it  is 
important that the polymer chains contain a substantial 
degree of flexib ility in order to achieve the desired 
entanglement with the mucus. In general, mobility and 
flexib ility of polymers can be related to their 
viscosities and diffusion coefficients, where higher 
flexib ility of a polymer causes greater diffusion into 
the mucus network
 38
.  
1.3. Hydrogen bonding capacity 
Hydrogen bonding is another important factor in 
mucoadhesion of a polymer. Park and Robinson found 
that in order for mucoadhesion to occur, desired 
polymers must have functional groups that are able to 
form hydrogen bonds 
39
. They have also confirmed  
that flexibility of the polymer is important to improve 
this hydrogen bonding potential. Polymers such as 
poly(vinyl alcohol), hydroxylated methacrylate, and 
poly(methacrylic acid ), as well as all their 
copolymers, are polymers with good hydrogen 
bonding capacity
10
. 
 
 
Figure 3: effect of polymer properties on mucoadhesion 
1.4. Cross-linking density  
The average pore size, the number average molecu lar 
weight of the cross-linked polymers, and the density 
of cross-linking are three important and interrelated 
structural parameters of a polymer network
59
. 
Therefore, it seems reasonable that with increasing 
density of cross-linking, diffusion of water into the 
polymer network occurs at a lower rate which, in turn, 
causes an insufficient swelling of the polymer and a 
decreased rate of interpenetration between polymer 
and mucin
38
. Flory has reported this general property 
of polymers, in which the degree of swelling at 
equilibrium has an inverse relationship with the 
degree of cross-linking of a polymer
 40
.  
1.5. Charge on polymer 
Some generalizations about the charge of bioadhesive 
polymers have been made previously, where nonionic 
polymers appear to undergo a smaller degree of 
adhesion compared to anionic polymers. Peppas and 
Buri have demonstrated that strong anionic charge on 
the polymer is one of the required characteristics for 
mucoadhesion
 10
. It has been shown that some cationic 
polymers are likely to demonstrate superior 
mucoadhesive properties, especially in a neutral or 
slightly alkaline medium
 41
. Additionally, some 
cationic high-molecular-weight polymers, such as 
chitosan, have shown to possess good adhesive 
properties.  
1.6. Concentration  
The importance of this factor lies in the development 
of a strong adhesive bond with the mucus, and can be 
explained by the polymer chain length available for 
penetration into the mucus layer. When the 
concentration of the polymer is too low, the number of 
penetrating polymer chains per unit volume of the 
mucus is small, and the interaction between polymer 
and mucus is unstable
9
. In general, the more 
concentrated polymer would result in a longer 
penetrating chain length and better adhesion. 
However, for each polymer, there is a critical 
concentration, above which the polymer produces an 
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―unperturbed‖ state due to a significantly coiled  
structure. As a result, the accessibility of the solvent to 
the polymer decreases, and chain penetration of the 
polymer is drastically reduced. Therefore, higher 
concentrations of polymers do not necessarily improve 
and, in some cases, actually diminish mucoadhesive 
properties. One of the studies addressing this factor 
demonstrated that high concentrations of flexible 
polymeric films based on polyvinylpyrrolidone or 
poly (vinyl alcohol) as film-forming polymers did not 
further enhance the mucoadhesive properties of the 
polymer
 42
.  
1.7. Hydration (swelling): 
Hydration is required for a mucoadhesive polymer to 
expand and create a proper ―macromolecular mesh‖ of 
sufficient size, and also to induce mobility in  the 
polymer chains in order to enhance the 
interpenetration process between polymer and 
mucin
38
. Polymer swelling permits a mechanical 
entanglement by exposing the bioadhesive sites for 
hydrogen bonding and/or electrostatic interaction 
between the polymer and the mucous network
 38
. 
However, a critical degree of hydration of the 
mucoadhesive polymer exists where optimum 
swelling and bioadhesion occurs
 10
. 
1.8 Initial contact time: 
The initial contact time between mucoadhesive and the 
mucus layer determines the extent of swelling and the 
interpenetration of polymer chains. Although with the 
initial pressure the initial contact time can dramatically  
affect the performance of a system the mucoadhesive 
strength increases as the initial contact time increases.
 43
 
2. Environmental factors 
The mucoadhesion of a polymer not only depends on its 
molecular properties, but also on the environmental factors 
adjacent to the polymer. Saliva, as a dissolution mediu m, 
affects the behavior of the polymer. Depending on the 
saliva flow rate and method of determination, the pH of 
this medium has been estimated to be between 6.5 and 7.5. 
The residence time of dosage forms is limited by the 
mucin turnover time, which has been calculated to range 
[
and 270 min in rats
 44 
and 12–24 h in humans  45.  
 
Figure 4: effect of mucosal environment on mucoadhesion 
Movement of the buccal tissues while eating, drinking, and 
talking, is another concern which should be considered 
when designing a dosage form for the oral cavity. 
Movements within the oral cav ity continue even during 
sleep, and can potentially lead to the detachment of the 
dosage form. Therefore, an optimum time span for the 
administration of the dosage form is necessary in order to 
avoid many of these interfering factors
 46
. 
3. Physiological Variables  
3.1 Applied strength:  
To place a solid bioadhesive system, it is necessary to 
apply a defined strength. The adhesive strength increases 
with the applied strength or with the density of its 
application up to an optimum. The pressure initially  
applied to the mucoadhesive tissue contact site can affect 
the depth of interpenetration. If h igh pressure is applied for 
a satisfactory longer period of time polymers become 
mucoadhesive even though they do not have attractive 
interaction with mucins
43, 47
.
  
3.2 Secretion of the model substrate surface:  
Since physical and biological changes may occur in the 
mucus gels on tissues under experimental conditions, the 
variability of biological substrate should be confirmed by 
examining properties like permeability, electro physiology, 
or histology etc. Such studies may be necessary before and 
after preparing the in vitro tests using tissues for the better 
in vitro / in vivo correlation.
48, 49
 
3.3 Disease state:  
The physicochemical properties of the mucus are known to 
change during disease conditions such as common cold, 
gastric ulcers, u lcerative colitis, cystic fibrosis, bacterial 
and fungal infections of the female reproductive tract and 
inflammatory conditions of the eye. The exact structural 
changes taking place in mucus under these conditions are 
not clearly understood. If mucoadhesive are to be used in 
the diseased state, the mucoadhesive property needs to be 
evaluated under it.
43, 48
 
ADVANTAGES OF BUCCAL ADHES IVE DRUG 
DELIVERY S YS TEM
 50, 51
 
1. Ease of administration.  
2. Systemic absorption is rapid. 
3. The buccal mucosa is highly perfused with blood 
vessels and offers a greater permeability than the skin.  
4. Permits localizat ion of drug to the oral cavity for a 
prolonged period of time.  
5. Can be admin istered to unconscious patients.  
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6. Offers an excellent route, for the systemic delivery of 
drugs with high first pass metabolis m, thereby 
offering a greater bioavailability.  
7. Reduction in dose results reducing dose related side 
effects.  
8. Drugs which destroyed by enzymatic, alkaline or 
acidic environment can be admin istered by this route.  
9. Drugs with poor b ioavailability via the oral route can 
be administered conveniently.  
10. It offers a passive system of drug absorption and does 
not require any activation.  
11. The presence of saliva ensures relatively large amount 
of water for drug dissolution. 
12. This route provides an alternative for the 
administration of various hormones, narcotic 
analgesic, steroids, enzymes, cardiovascular agents 
etc.  
13. Termination of therapy is easy.  
LIMITATIONS OF BUCCAL ADHES IVE DRUG 
ADMINIS TRATION
 50, 51
 
Drugs, which irritate the oral mucosa, haves 
unpleasant taste/odor, cannot be administered by this 
route.  
1. Drugs which are unstable at buccal pH cannot be 
administered by this route.  
2. Only drugs with small dose requirements can be 
administered.  
3. Drugs may swallow with saliva and loses the 
advantages of buccal route.  
4. Only those drugs, which are absorbed by passive 
diffusion, can be admin istered by this route.  
5. Swallowing of the formulat ion by the patient may be 
possible.  
GENERAL CONSIDERATIONS IN DES IGNING OF 
BUCCAL DOSAGE FORMS  
1. Physiological aspects/Role of Saliva and Mucus:  
Constant flow of saliva and mobility of the involved 
tissues challenge drug delivery to the oral cavity. The 
residence time of drugs delivered to the oral cavity is 
typically short, in the range of 5–10 min9. Buccal 
mucoadhesive formulations are expected to overcome this 
problem. Bioadhesive polymers offer a means by which a 
delivery system is attached to the buccal mucosa, and 
hence, provide substantially longer retention times at the 
absorption site. They also provide a means to confine and 
maintain high local concentrations of the drug and/or 
excip ient(s) to a defined, relatively small region of the 
mucosa in order to minimize loss to other regions and limit  
potential side effects. 
The buccal mucosa is a very suitable region for 
bioadhesive system application because of its smooth and 
relatively immobile surface, as well as direct accessibility. 
However, there are some inherent limitations associated 
with buccal drug delivery, including short residence time, 
small absorption area, and barrier properties of the buccal 
mucosa. The size of a buccal dosage form is restricted by 
the very limited area availab le for applicat ion of the 
delivery system. 
This size restriction, in turn, limits the amount of drug that 
can be incorporated in the dosage forms. In general, a 
buccal delivery device that is 1–3 cm2 in size 52 and a drug 
with a daily dose requirement of 25 mg or less 
7
 would be 
preferred. In addition, an ellipsoid shape appears to be 
most acceptable 
52
, and the thickness of buccal delivery 
devices is usually limited to a few millimeters 
53
. 
The mucus layer covering the buccal mucosa is necessary 
for bioadhesive systems. Unfortunately, it not only forms a 
physical barrier to drug permeation, but also prevents long-
term bioadhesion and sustained drug release by its short 
turnover time. Interestingly, the presence of bioadhesive 
polymers on a mucous membrane might alter the turnover 
of mucin, since the residence time of mucoadhesives are 
usually longer than the reported mucin turnover time 
9
. 
Nevertheless, the maximum duration for buccal drug 
delivery is usually limited to approximately 4–6 h, since 
meal intake and/or drinking may require dosage form 
removal 
54
. 
2.  Pathological aspects: 
Many diseases can affect the thickness of the epithelium, 
resulting in alterat ion of the barrier property of the 
mucosa. Some d iseases or treatments  may also influence 
the secretion and properties of the mucus 
55
, as well as the 
saliva. Changes at the mucosal surface due to these 
pathological conditions may complicate the application 
and retention of a bioadhesive delivery device. Therefore, 
understanding the nature of the mucosa under relevant 
disease conditions is necessary for designing an effective 
buccal delivery system. In addit ion, drugs with the 
potential of changing the physiological conditions of the 
oral cavity may not be suitable for buccal delivery.
 
 
Figure 5: Basic considerations in Design of Buccal Adhesive Dosage forms  
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3. Pharmacological aspects: 
A buccal dosage form may be designed to deliver a drug to 
the systemic circulation, or merely indicated for local 
therapy of the oral mucosa. Select ion of dosage forms is 
affected by the intended application, target site of action, 
drug characteristics, and the site to be treated (periodontal 
pockets, gingival, teeth, buccal mucosa, or systemic).  
4.  Pharmaceutical aspects: 
Factors affecting both drug release and penetration through 
buccal mucosa must also be considered in the formulat ion 
design. In addition to the physicochemical characteristics 
required for desirable drug release and absorption, 
organoleptic properties of the drug or the delivery device 
should also be considered, since the buccal delivery  
systems are to be exposed to a highly developed sensory 
organ. 
A. Selection of drug: 
Poor drug solubility in saliva could significantly retard  
drug release from the dosage form. Various solubilizers 
have been used to solubilized and increase the absorption 
of poorly water-soluble drugs delivered via the buccal 
mucosa.  
Criteria for selection of drug for buccal adhesive 
delivery: 
1. Drugs those are primarily absorbed in buccal cavity; 
2. Drugs those are easily permeate through buccal 
mucosa 
3. Drugs those degrade in the G.I.T. 
4. Drugs acting locally in the buccal cavity; 
5. Drugs which are absorbed by passive diffusion 
6. Drug those have small dose are suitable. 
B. Selection of formulation excipients 
Selection of formulation excipients is yet another 
important consideration, since acidic compounds can 
stimulate the secretion of saliva, which enhances not only 
drug dissolution, but also drug loss by involuntary 
swallowing. Besides, addition of a separate additive for 
each function could complicate and enlarge the dosage 
form, which might be problematic for buccal applications. 
Therefore, as mentioned previously, polymers with 
multip le functions seem promising.  
C. Permeation Enhancers: 
Permeability characteristics of the buccal mucosa may be 
continually changed by the rapid turnover of the buccal 
epithelium (3–8 days compared to about 30 days for the 
skin 
8
). Generally, the buccal mucosa is considerably less 
permeable, and hence, does not provide rapid absorption 
and good bioavailability seen with sublingual 
administration. Permeability of the buccal mucosa can be 
increased by various penetration enhancers capable of 
increasing cell membrane fluidity, ext racting the structural 
intercellular and/or intracellu lar lipids, altering cellu lar 
proteins, or altering mucus structure and rheology 
56
.  
Incorporation of unsaturated fatty acids into the 
mucoadhesive polymers has been shown to be effective in 
buccal delivery of drugs. The mechanism for the 
permeability enhancement by unsaturated fatty acids is 
through increasing the fluidity of the membrane 
phospholipids. This class of permeation enhancers 
reversibly alters the physical structure of the membrane by 
incorporating themselves into the phospholipid membrane.  
Table 1: Mucosal penetration enhancers and mechanisms of action  
CLASSIFICATION  EXAMPLES  MECHANISM 
Surfactants Anionic: sodium lauryl sulphate 
Cationic: cetylpyridinium chloride 
Nonionic: poloxamer, span,  tween 
Perturbation of intercellular lipid,  
protein domain integrity, 
Distrusts membrane, 
Bile salts Sodium glycodeoxycholate,  
Sodium glycocholate,  
Sodium taurodeoxycholate,  
Distrusts membrane, 
Open tight junctions, 
Mucolytic activity 
Cyclodextrins 
 
α, β, γ-cyclodextrin, Methylated  
β–cyclodextrins  
Inclusion of membrane Compounds, 
Open Tight junctions 
Fatty acids  Oleic Acid, Lauric Acid,  Caprylic 
Acid, Phosphotidylcholine 
Increase fluidity of phospholipid domains, 
Distrusts membrane 
Cationic compounds Poly-L-arginine, L-lysine Ionic interaction with negative charge on the mucosal surface 
Chelators  EDTA, Citric Acid, Na-citrate Interfere with Ca Polyacrylates 
Cationic polymers Chitosan, Trimethyl chitosan Ionic interaction with negative charge on the mucosal surface 
Mucoadhesive Polymers Carbopol, Starch, Chitosan Reduce nasal clearance,  
Open tight junctions 
 
D. Enzyme Inhibition: 
Even though the enzyme activity in the buccal mucosa is 
relatively low and, as a result, drug inactivation is slower 
and less extensive than in other mucosal routes 
57
, 
susceptible drugs, especially peptides and proteins, can 
still be degraded by the enzymes in saliva and buccal 
mucosa. Therefore, enzyme inhibitors may be incorporated 
in the dosage forms to increase drug bioavailability. some 
bioadhesive polymers, such as poly(acrylic acid), 
polycarbophil, and carbopol, can also inhibit certain 
proteolytic enzymes (trypsin, a-chymotrypsin, 
carboxypeptidases A and B, and leucine aminopeptidase) 
58
. However, cysteine protease 
(pyroglutamyl aminopeptidase) may not be inhibited by 
polycarbophil and carbopol 
58
. 
E. pH of Formulation 
Maximal permeation occurs at the pH at which these drugs 
are predominantly in the unionized fo rm. Control of pH is 
critical for successful buccal delivery of ionizab le drugs. 
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Saliva has a weak buffering capacity to maintain pH value 
within local regions. It might be desirable to include some 
pH modifiers in the formulation in order to temporarily  
modulate the microenvironment at the application site for 
better drug absorption. 
It is worth noting that pH can also influence the charge on 
the surface of the mucus, as well as certain ionizable 
groups of the polymers, which might affect the strength of 
mucoadhesion. In addition, it has been shown that the pH 
of the medium influences the degree of hydration of cross -
linked poly(acry lic acid), e.g. polycarbophil 
59-60
. 
Therefore, the pH needs to be carefully chosen to optimize 
both drug permeat ion and mucoadhesion. 
ORAL MUCOSA AS A BARRIER TO DRUG 
PERMEABILITY 
A. Oral Mucosal epithelium as a barrier to 
permeability: 
Oral mucosa containing epithelium acts as a protective 
layer for the tissues beneath and as a barrier to the entry of 
foreign material and microorganisms. However, oral 
mucosa is 4–4000 times more permeable than that of skin 
61
. 
The permeability barrier property of the oral mucosa is 
predominantly due to intercellu lar materials derived from 
the so-called membrane coating granules (MCGs) 
8
. MCGs  
are spherical or oval organelles that are 100–300 nm in  
diameter and found in both keratin ized and non-keratinized  
epithelia. MCGs were first named as such because it was 
believed that they were subject to exocytosis from the 
cytoplasm of the stratum spinosum of keratin ized epithelia 
following thickening of these cells. Nonetheless, it is 
actually the contents of MCGs that are subject to 
exocytosis prior to the onset of membrane thickening. 
MCGs are found near the upper, distal, or superficial 
border of the cells, and a few occur near the opposite 
border 
62
 and references therein). Several hypotheses have 
been suggested to describe the functions of MCGs, 
including a membrane thicken ing effect, cell adhesion, 
production of a cell surface coat, cell desquamation, and 
permeability barrier. Hayward has reviewed the literature 
related to these functions, and it appears that the 
permeability barrier is most often attributed to MCGs 
62
. 
They discharge their contents into the intercellular space to 
ensure epithelial cohesion in the superficial layers, and this 
discharge forms a barrier to the permeability of various 
compounds. Cultured oral epithelium devoid of MCGs has 
been shown to be permeable to compounds that do not 
typically penetrate oral ep ithelium 
63
. This same pattern is 
observed in both keratinized and nonkeratinized epithelia 
8
, which indicates that keratinization of the epithelia, in  
and of it is not expected to play a major role as a barrier to 
permeat ion 
64
. 
B. Enzymes as a barrier to permeability 
Another barrier to drug permeability across buccal 
epithelium is enzymat ic degradation. Saliva contains no 
proteases, but does contain moderate levels of esterases, 
carbohydrases, and phosphatases 
65
. 
However, several proteolytic enzymes have been found in 
the buccal epithelium 
16
. Walker et al.
 66
 reported that 
endopeptidases and carboxypeptidases were not present on 
the surface of porcine buccal mucosa, whereas 
aminopeptidases appeared to be the major enzymatic 
barrier to the buccal delivery of peptide drugs. 
Aminopeptidase N and A (plasma membrane-bound 
peptidases) and aminopeptidase B (cytosolic enzyme) have 
been found in the buccal tissue 
67
. The use of 
mucoadhesive polymers as enzyme inhib itor agents has 
been developed to overcome this obstacle in peptide and 
protein delivery. 
MUCOADHES IVE POLYMERS AS ENZYME 
INHIBITORS AND PERMEATION ENHANCERS  
It has been shown that some mucoadhesive polymers can 
act as an enzyme inhib itor. The particular importance of 
this finding lies in delivering therapeutic compounds that 
are specifically prone to extensive enzymatic degradation, 
such as protein and polypeptide drugs. Investigations have 
demonstrated that polymers, such as poly(acrylic acid), 
operate through a competitive mechanism with proteolytic 
enzymes. 
This stems from their strong affinity to divalent cations 
(Ca2+, Zn2+) 
68-69
. These cations are essential cofactors for 
the metalloproteinases, such as trypsin. 
Circular dichrois m studies suggest that Ca2+ depletion, 
mediated by the presence of some mucoadhesive 
polymers, causes the secondary structure of trypsin to 
change, and initiates a further autodegradation of the 
enzyme 
68-69
. 
The increased intestinal permeability of various drugs in 
the presence of numerous mucoadhesive polymers has also 
been attributed to their ability to open up the tight 
junctions by absorbing the water fro m the epithelial cells. 
The result of water absorption by a dry and swellable 
polymer is dehydration of the cells and their subsequent 
shrinking. Th is potentially results in an expansion of the 
spaces between the cells (increased radius of the 
paracellu lar pathway) 
70-71
. 
The use of multifunctional matrices, such as polyacrylates, 
cellu lose derivatives, and chitosan, that display 
mucoadhesive properties, permeation-enhancing effects, 
enzyme-inhibiting properties, and/or a high buffer capacity 
have proven successful strategies in oral drug delivery 
72
. 
The inhibition of the major proteolytic enzymes by these 
polymers is remarkab le and represents yet another possible 
approach for the delivery of therapeutic compounds, 
particularly protein and peptide drugs, through the buccal 
mucosa. 
Any newly developed excip ients are likely to be subject to 
safety and toxicity testing to ensure the safety of these 
new-generation bioadhesive polymers. 
Since lect ins are found in many species in the plant 
kingdom (e.g. tomato, wheat germ, mistletoe), they are not 
likely to be toxic. The fact that the source plants can be 
consumed raw, e.g. tomato fruit, would seem to suggest 
the safety of lectins. As mentioned previously, tomato 
lectin has been shown to bind to the surface of several cell 
monolayers, as well as rat intestinal epithelium without 
causing any harmfu l effects to the membranes. Another 
example is the clinical application of mistletoe lectin  
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(Viscum album) for antitumor therapy in rabbits and 
cancer patients 
73
. To achieve the desired level of 
cytoadhesion, genetically engineered lectins or 
lectinomimetics with reduced toxicity/immunogenicity 
could also be used. In contrast, haemagglutinin from red  
kidney beans (Phaseolus vulgaris) and bacterial adhesive 
proteins might require more extensive testing. 
Interestingly, thiolated compounds exhibited a 
significantly lower membrane-damaging effect than the 
unmodified compounds after a 1-h incubation of rat red 
blood cells with a 0.025% solution of each compound. The 
lower membrane-damaging effect of 
thiolated chitosan was attributed to the increased rigid ity 
of the molecule due to intra- and intermolecular d isulfide 
bonds, leading to reduced attachment to the cell 
membrane.  
An enhanced cytotoxicity of thio lated chitosan at 
concentrations of 0.25% and 0.5% was attributed to the 
increase in molecular weight and viscosity due to 
crosslinking via disulfide bond format ion. It was 
concluded that these thiolated compounds displayed a low 
cytotoxicity profile comparable to that of the unmodified  
controls, which should not compromise their potential use 
in drug delivery. 
Table 2: Research carried out on various buccal adhesive polymers  
BUCCAL ADHESIVE MATERIAL(S) AIM OF THE RESEARCH 
HPC & CP  Preferred mucoadhesive strength on CP, HPC, HPC-CP combination74 
HPC and CP Measured bioadhesive property using mouse peritoneal membrane75  
CP, HPC, PVP, CMC  Studied interpolymer complexation and its effects on bioadhesive strength76  
CP & HPMC  Controlled-release delivery77 
HPC, HEC, PVP, PVA  Tested mucosal adhesion on patches with two-ply laminates with an impermeable backing 
layer and hydrocolloid polymer layer78 
CP, PIP & PIB bioadhesive buccal patch formulation79 
Xanthum & locust bean gum Hydrogel formation by combination of natural gums80  
Chitosan, HPC, CMC, pectin, PC Evaluate mucoadhesive properties by routinely measuring the detachment force from pig 
intestinal mucosa[41] 
HEC synthesis of a bilayer patch for thyroid gland diagnosis81 
PC Design of unidirectional buccal patch for delivery of peptide drugs82 
HEMA with Poly tetramethylene glycol Bioadhesive buccal hydrogel for controlled-release delivery of buprenorphine83 
Polymer blend of CP, PIB Patch system for buccal mucoadhesive drug delivery 84 
PVP, CP, CPC Device for oramucosal delivery of LHRH-device containing a fast release and a slow 
release layer85 
CMC, CP-974P, CP-EX55 pectin, CC Mucoadhesive gels for intraoral delivery 86 
HPMC, PC Buccal mucoadhesive tablets yielding the highest force of adhesion33  
PVP, PAA  Transmucosal controlled delivery of isosorbide dinitrate87,88  
Maize starch, CP 974P, SSF Bioadhesive erodible buccal tablet for progesterone delivery 89 
Natural oligosaccharide gum,  Mucoadhesive buccal tablets for sustained release of salmon calcitonin90  
P(AA-co-EHA) Evaluation of P(AA-co-EHA) films for buccal mucoadhesive drug delivery 91 
HPC & CP Used HPC-CP powder mixture as peripheral base for strong adhesion and HPC-CP freeze-
dried mixture as core base92  
Cetylpyridinium chloride=CPC, SSF= Sodium Stearylfumarate, P(AA-co-EHA)= Poly(acrylic acid-co-ethylhexyl acrylate), 
CP=Carbopol, PC=Polycarbophil, CC= Chitosan chloride 
 
CONCLUS ION: 
During the last few years research on buccal drug delivery 
has revealed considerable growth and advances. Among 
the various transepithelial sites available, the oral mucosa 
is the most convenient and accessible. If low drug 
concentrations are required to gain access to the blood, the 
transbuccal route may be very satisfactory, provided the 
physicochemical properties of a given drug allow 
permeat ion through the mucosa. Buccal mucosa allows 
drug delivery for both local and systemic therap ies. 
Despite the advantages of delivering drugs through buccal 
mucosa, the formulat ive approach alone is not sufficient 
for an effective delivery control. The intrinsic 
physicochemical properties of the drug, such as solubility, 
partitioning, stability, crystallinity, thermodynamic 
activity, molecular size, pKa and half-life, can constitute 
limit ing factors to drug absorption. Therefore deep 
understanding of the various variables which affecting the 
delivery of drug through buccal mucosa is the most 
important considerations before designing of such drug 
delivery system.  
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